News - Brintellix

Filter

Current filters:

Brintellix

Popular Filters

Brintellix meets primary efficacy end-point in depression study

Brintellix meets primary efficacy end-point in depression study

26-06-2014

Danish CNS drug specialist Lundbeck has announced results of the SOLUTION trial conducted in Asian patients…

BrintellixDenmarkLundbeckNeurologicalPharmaceuticalResearch

Brintellix superior to escitalopram in improving sexual functioning for MDD patients

Brintellix superior to escitalopram in improving sexual functioning for MDD patients

17-06-2014

Danish CSN drug specialist Lundbeck has presented results about sexual functioning from a head-to-head…

BrintellixEscitalopram OxalateLundbeckMen's HealthNeurologicalPharmaceuticalResearch

Lundbeck’s Brintellix shows efficacy in cognitive function study

Lundbeck’s Brintellix shows efficacy in cognitive function study

16-06-2014

Danish CNS drug specialist Lundbeck has announced results from the CONNECT study showing that Brintellix…

BrintellixDenmarkDepressionLundbeckNeurologicalPharmaceuticalResearch

Lundbeck’s Brintellix available in US pharmacies for depression

Lundbeck’s Brintellix available in US pharmacies for depression

22-01-2014

Lundbeck (LUN: CO) and Takeda Pharmaceutical (TYO: 4502) jointly announced today that Brintellix (vortioxetine)…

BrintellixLundbeckMarkets & MarketingNeurologicalPharmaceuticalRegulationTakeda PharmaceuticalsUSA

Lundbeck’s Brintellix OKed in Europe for adults with depression

Lundbeck’s Brintellix OKed in Europe for adults with depression

29-12-2013

The European Commission has granted marketing authorization for Danish CNS specialist Lundbeck’s Brintellix…

BrintellixLundbeckNeurologicalPharmaceuticalRegulation

Lundbeck’s Brintellix scores well in new cognitive performance study

Lundbeck’s Brintellix scores well in new cognitive performance study

11-12-2013

Danish CNS specialist Lundbeck has released results from FOCUS, a new study showing that Brintellix (vortioxetine)…

BrintellixLundbeckNeurologicalPharmaceuticalResearch

Positive EMA/CHMP opinions for Actelion and Lundbeck

Positive EMA/CHMP opinions for Actelion and Lundbeck

27-10-2013

At its October month-end meeting, the European Medicines Agency’s Committee for Medicinal Products…

ActelionBiotechnologyBrintellixEuropeLundbeckNeurologicalOpsumitPharmaceuticalRegulationRespiratory and Pulmonary

US FDA approves new drug Brintellix to treat major depressive disorder

US FDA approves new drug Brintellix to treat major depressive disorder

01-10-2013

The US Food and Drug Administration approved Brintellix on Monday, co-marketed by Takeda and Lundbeck…

BrintellixLundbeckNeurologicalNorth AmericaPharmaceuticalRegulationTakeda Pharmaceuticals

Lundbeck and Takeda's Brintellix shows positive results in Ph III major depression study

20-05-2013

Danish CNS specialist Lundbeck (LUND: DC) and partner Takeda Pharmaceutical (TYO: 4502), Japan's largest…

BrintellixLundbeckNeurologicalPharmaceuticalResearchTakeda Pharmaceuticalsvortioxetine

Lundbeck announces positive results for Brintellix and Selincro

08-04-2013

Danish CNS drug specialist Lundbeck (LUND: C) A/S this morning released positive results for the REVIVE…

BrintellixLundbeckNeurologicalPharmaceuticalResearchSelincro

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top